Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy. METHODS: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. RESULTS: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events. CONCLUSIONS: Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical benefi t with maintenance ICT in specifi c settings was demonstrated in patients with nonsmall cell lung cancer (NSCLC; ref.50 ), extensive-stage small cell lung cancer ( 51,52 ), and bladder cancer ( 53 ), leading to FDA approvals in these tumor types.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [50]
In the citing paper
“By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC57–59”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4824 · Cited by 573
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7840 · Cited by 491
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E. E., Lim, E., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 490
Research works printed but not linked: 1
- Ettinger S, Wood DE, Aisner DL, et al. Non-small cell lung cancer, Version 5.2017. J Natl Compr Canc Netw 2017; 15: 504-35.
Cited by
Items 401–500 of 1,008
Guo, L., Wei, R., Lin, Y., & Kwok, H. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01508 · Cited by 89
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Russell, B. L., Sooklal, S. A., Malindisa, S. T., Daka, L. J., & Ntwasa, M. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641428 · Cited by 86
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 89
Shen, H., Ojo, O. A., Ding, H., Mullen, L. J., Xing, C., Hossain, M. I., Yassin, A., Shi, V. Y., Lewis, Z., Podgórska, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53593-8 · Cited by 101
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
Liang, Y., Liu, X., Shen, L., Hu, G., Zou, G., Zhang, N., Chen, C., Chen, X., Zhu, X., Yuan, Y., et al. (2025) · JAMA · doi:10.1001/jama.2025.1132 · Cited by 87
Self-citationZhu, J., Li, R., Tiselius, E., Roudi, R., Teghararian, O., Suo, C., & Song, H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011300.pub2 · Cited by 83
Chicas-Sett, R., Morales-Orue, I., Castilla-Martinez, J., Zafra, J., Kannemann, A., Blanco, J., Lloret, M., & Lara, P. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092173 · Cited by 88
Peng, L., Qin, B., Xiao, K., Xu, S., Yang, J., Zang, Y., Stebbing, J., & Xie, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1781333 · Cited by 89
Scoccianti, S., Olmetto, E., Pinzi, V., Osti, M. F., Franco, R. D., Caini, S., Anselmo, P., Matteucci, P., Franceschini, D., Mantovani, C., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab129 · Cited by 94
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
Li, H., Zandberg, D. P., Kulkarni, A., Chiosea, S. I., Santos, P. M., Isett, B. R., Joy, M., Sica, G., Contrera, K. J., Tatsuoka, C. M., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.026 · Cited by 106
Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies
Fishman, J. A., Hogan, J. I., & Maus, M. V. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1025 · Cited by 86
Song, P., Zhang, D., Cui, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13541 · Cited by 96
First line Immunotherapy for Non-Small Cell Lung Cancer
Nasser, N. J., Gorenberg, M., & Agbarya, A. (2020) · Pharmaceuticals · doi:10.3390/ph13110373 · Cited by 86
Evolving trends in lung cancer: Epidemiology, diagnosis, and management
Deshpand, R., Chandra, M., & Rauthan, A. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_52_21 · Cited by 95
Harnessing radiation to improve immunotherapy: better with particles?
Durante, M., & Formenti, S. C. (2019) · British Journal of Radiology · doi:10.1259/bjr.20190224 · Cited by 88
Liu, X., Guo, C., Tou, F., Wen, X., Kuang, Y., Zhu, Q., & Hu, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32744 · Cited by 87
Salehi‐Rad, R., Li, R., Paul, M. K., Dubinett, S. M., & Liu, B. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.003 · Cited by 94
Effects of Radiation on the Tumor Microenvironment
Monjazeb, A. M., Schalper, K. A., Villarroel‐Espíndola, F., Nguyen, A. T., Shiao, S. L., & Young, K. H. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.004 · Cited by 93
Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges
Qian, J. M., & Schoenfeld, J. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.608772 · Cited by 91
Yang, Y., Chong, Y., Chen, M., Dai, W., Zhou, X., Ji, Y., Qiu, G., & Du, X. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02825-2 · Cited by 92
Shaikh, M., Shinde, Y., Pawara, R. H., Noolvi, M. N., Surana, S. J., Ahmad, I., & Patel, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00876 · Cited by 85
Making cold malignant pleural effusions hot: driving novel immunotherapies
Murthy, P., Ekeke, C. N., Russell, K. L., Butler, S. C., Wang, Y., Luketich, J. D., Soloff, A. C., Dhupar, R., & Lotze, M. T. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1554969 · Cited by 86
Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety
Williamson, C. W., Sherer, M. V., Zamarin, D., Sharabi, A. B., Dyer, B. A., Mell, L. K., & Mayadev, J. (2021) · Cancer · doi:10.1002/cncr.33424 · Cited by 88
Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes
Osarogiagbon, R. U., Sineshaw, H. M., Unger, J. M., Acuña-Villaorduña, A., & Goel, S. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_323523 · Cited by 88
Suárez, C., Larkin, J., Patel, P. M., Valderrama, B. P., Rodríguez‐Vida, A., Glen, H., Thistlethwaite, F. C., Ralph, C., Srinivasan, G., Méndez, M. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01414 · Cited by 80
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC)
Yoneda, K., Imanishi, N., Ichiki, Y., & Tanaka, F. (2018) · Journal of UOEH · doi:10.7888/juoeh.40.173 · Cited by 84
The evolutionary legacy of immune checkpoint inhibitors
Kaushik, I., Ramachandran, S., Zabel, C., Gaikwad, S., & Srivastava, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.020 · Cited by 79
Manukian, G., Bar‐Ad, V., Lü, B., Argiris, A. E., & Johnson, J. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00122 · Cited by 85
Quantitative Prediction of the Landscape of T Cell Epitope Immunogenicity in Sequence Space
Ogishi, M., & Yotsuyanagi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00827 · Cited by 96
Chintakuntlawar, A. V., Yin, J., Foote, R. L., Kasperbauer, J. L., Rivera, M., Asmus, E. J., Garces, N. I., Janus, J. R., Liu, M. C., Ma, D. J., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0086 · Cited by 83
Faehling, M., Schumann, C., Christopoulos, P., Hoffknecht, P., Alt, J. A., Horn, M., Eisenmann, S., Schlenska‐Lange, A., Schütt, P., Steger, F., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.10.006 · Cited by 85
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
Bansal, D., Reimers, M. A., Knoche, E. M., & Pachynski, R. K. (2021) · Cancers · doi:10.3390/cancers13020334 · Cited by 85
Yu, R., Wang, W., Li, T., Li, J., Zhao, K., Wang, W., Liang, L., Wu, H., Ai, T.-S., Huang, W. J., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0632 · Cited by 79
TACHIHARA, M. Y., Tsujino, K., Ishihara, T., Hayashi, H., Sato, Y., Kurata, T., Sugawara, S., Shiraishi, Y., Teraoka, S., Azuma, K., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.3309 · Cited by 86
Peters, S., Dafni, U. G., Boyer, M. J., Ruysscher, D. D., Finn, C. F., Felip, E., Garrido, P., Girard, N., Gückenberger, M., Haanen, J. B. A. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy553 · Cited by 82
Self-citationImmune-Related Adverse Events: Pneumonitis
Zhong, L., Altan, M., Shannon, V. R., & Sheshadri, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_13 · Cited by 86
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 84
Desîlets, A., Blanc‐Durand, F., Lau, S. C. M., Hakozaki, T., Kitadai, R., Malo, J., Belkaïd, W., Richard, C., Messaoudene, M., Cvetkovic, L., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.008 · Cited by 83
A review of guidelines for lung cancer
Bironzo, P., & Maïo, M. D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.54 · Cited by 85
Lanier, C. M., Hughes, R. T., Ahmed, T., LeCompte, M. C., Masters, A. H., Petty, W. J., Ruiz, J., Triozzi, P. L., Su, J., O’Neill, S., et al. (2019) · Neuro-Oncology Practice · doi:10.1093/nop/npz004 · Cited by 79
Teng, F., Li, M., & Yu, J. (2020) · BMC Medicine · doi:10.1186/s12916-020-01718-3 · Cited by 86
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
Qu, J., Mei, Q., Liu, L., Cheng, T., Wang, P., Chen, L., & Zhou, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992968 · Cited by 86
Vinogradskiy, Y. Y., Castillo, R., Castillo, E. M., Schubert, L. K., Jones, B. L., Faught, A. M., Gaspar, L. E., Kwak, J., Bowles, D. W., Waxweiler, T. V., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.10.147 · Cited by 77
Zhang, Y., Sriramaneni, R. N., Clark, P. A., Jagodinsky, J. C., Ye, M., Jin, W., Wang, Y., Bates, A., Kerr, C. P., Le, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32645-x · Cited by 77
A Review of the Abscopal Effect in the Era of Immunotherapy
Nabrinsky, E., Macklis, J. N., & Bitran, J. D. (2022) · Cureus · doi:10.7759/cureus.29620 · Cited by 98
Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
Seliger, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00999 · Cited by 84
Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly
Shinde, A., Li, R., Kim, J. H., Salgia, R., Hurria, A., & Amini, A. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.06.002 · Cited by 89
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
Awadalla, M., Golden, D. L. A., Mahmood, S., Alvi, R. M., Mercaldo, N. D., Hassan, M. Z. O., Banerji, D., Rokicki, A., Mulligan, C. P., Murphy, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0535-y · Cited by 80
Wang, P., Fang, X., Yin, T., Tian, H., Yu, J., & Teng, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.628124 · Cited by 80
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer
Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023) · Pharmaceuticals · doi:10.3390/ph16101384 · Cited by 94
Toxicity in the era of immune checkpoint inhibitor therapy
Keam, S., Turner, N., Kugeratski, F. G., Rico, R., Colunga-Minutti, J., Poojary, R., Alekseev, S., Patel, A. B., Li, Y. J., Sheshadri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1447021 · Cited by 92
Fumet, J.-D., Limagne, E., Thibaudin, M., & Ghiringhelli, F. (2020) · Cancers · doi:10.3390/cancers12092637 · Cited by 85
PD-1/PD-L1 Axis in Lung Cancer
Santini, F. C., & Hellmann, M. D. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000300 · Cited by 83
Barrett, M. T., Lenkiewicz, E., Malasi, S., Basu, A., Yearley, J. H., Annamalai, L., McCullough, A. E., Kosiorek, H., Narang, P., Sayres, M. A. W., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1004-0 · Cited by 77
El-Osta, H. E., & Jafri, S. H. R. (2019) · Immunotherapy · doi:10.2217/imt-2018-0086 · Cited by 78
Le, Q., Colevas, A. D., O’Sullivan, B., Lee, A. W. M., Lee, N. Y., Ma, B. B. Y., Siu, L. L., Waldron, J. N., Lim, C. M., Riaz, N., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz044 · Cited by 78
Immunotherapy in breast cancer
Bayraktar, S., Batoo, S. A., Okuno, S. H., & Glück, S. (2019) · Journal of Carcinogenesis · doi:10.4103/jcar.jcar_2_19 · Cited by 84
Procureur, A., Simonaggio, A., Bibault, J., Oudard, S. M., & Vano, Y. A. (2021) · Cancers · doi:10.3390/cancers13040678 · Cited by 82
Yang, Q., Chen, M., Gu, J., Niu, K., Zhao, X., Zheng, L., Xu, Z., Yu, Y., Li, F., Meng, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.665133 · Cited by 83
Chau, J., Yadav, M., Liu, B., Furqan, M., Dai, Q., Shahi, S., Gupta, A., Mercer, K. N., Eastman, E., Hejleh, T. A., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08530-z · Cited by 73
Voissière, A., Gomez‐Roca, C., Chabaud, S., Rodriguez, C., Nkodia, A., Berthet, J., Montané, L., Bidaux, A.-S., Treilleux, I., Eberst, L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.add1834 · Cited by 83
Sandbhor, P., Palkar, P., Bhat, S., John, G., & Goda, J. S. (2024) · Nanoscale · doi:10.1039/d3nr06131k · Cited by 86
Immune Checkpoint Inhibitor-Related Pneumonitis
Gomatou, G., Tzilas, V., Kotteas, E., Syrigos, K., & Bouros, D. (2020) · Respiration · doi:10.1159/000509941 · Cited by 75
Sun, A. Y., Hu, C., Wong, S. J., Gore, E., Videtic, G. M. M., Dutta, S. W., Suntharalingam, M., Chen, Y., Gaspar, L. E., & Choy, H. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7220 · Cited by 79
Nemoto, T., Futakami, N., Yagi, M., Kumabe, A., Takeda, A., Kunieda, E., & Shigematsu, N. (2019) · Journal of Radiation Research · doi:10.1093/jrr/rrz086 · Cited by 74
Sławiński, G., Wrona, A., Dąbrowska-Kugacka, A., Raczak, G., & Lewicka, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197195 · Cited by 82
Johnsrud, A. J., Jenkins, S. V., Jamshidi‐Parsian, A., Quick, C. M., Galhardo, E. P., Dings, R. P. M., Vang, K. B., Narayanasamy, G., Makhoul, I., & Griffin, R. J. (2020) · Radiation Research · doi:10.1667/rade-20-00065.1 · Cited by 82
Cousin, F., Desir, C., Mustapha, S. B., Mievis, C., Coucke, P. A., & Hustinx, R. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.01.001 · Cited by 82
Clinical Development of Novel Drug–Radiotherapy Combinations
Ahmad, S. S., Crittenden, M. R., Tran, P. T., Kluetz, P. G., Blumenthal, G. M., Bulbeck, H., Baird, R. D., Williams, K. J., Illidge, T., Hahn, S. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2466 · Cited by 75
Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer
Meyers, D. E., Bryan, P., Banerji, S. O., & Morris, D. G. (2018) · Current Oncology · doi:10.3747/co.25.3976 · Cited by 76
Galli, G., Triulzi, T., Proto, C., Signorelli, D., Imbimbo, M., Poggi, M. M., Fucà, G., Ganzinelli, M., Vitali, M., Palmieri, D., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.008 · Cited by 76
Katayama, Y., Shimamoto, T., Yamada, T., Takeda, T., Yamada, T., Shiotsu, S., Chihara, Y., Hiranuma, O., Iwasaku, M., Kaneko, Y., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010102 · Cited by 75
Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
Zaborowska-Szmit, M., Krzakowski, M. J., Kowalski, D. M., & Szmit, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051268 · Cited by 76
Risk factors for immune-related adverse events: what have we learned and what lies ahead?
Liu, X., Shi, Y., Zhang, D., Zhou, Q., Liu, J., Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2021) · Biomarker Research · doi:10.1186/s40364-021-00314-8 · Cited by 79
Cetuximab for treating non-small cell lung cancer
Mazzarella, L., Guida, A., & Curigliano, G. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1452906 · Cited by 86
Verma, V., Cushman, T. R., Selek, U., Tang, C. Z., & Welsh, J. W. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.04.054 · Cited by 74
Zhang, T. W., Snir, J. A., Boldt, G., Rodrigues, G., Louie, A. V., Gaede, S., McGarry, R. C., Urbanic, J. J., Daly, M. E., & Palma, D. A. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.12.044 · Cited by 74
Hu‐Lieskovan, S., Lisberg, A. E., Zaretsky, J. M., Grogan, T., Rizvi, H. A., Wells, D. K., Carroll, J., Cummings, A. L., Madrigal, J., Jones, B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4275 · Cited by 77
Thor, M., Deasy, J. O., Hu, C., Gore, E., Bar‐Ad, V., Robinson, C. G., Wheatley, M., Oh, J. H., Bogart, J. A., Garces, Y. I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2627 · Cited by 73
Immunotherapy in Older Adults With Cancer
Presley, C. J., Gomes, F., Burd, C. E., Kanesvaran, R., & Wong, M. L. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00138 · Cited by 76
Chen, X., Sheikh, K., Nakajima, E. C., Lin, C. T., Lee, J., Hu, C., Hales, R. K., Forde, P. M., Naidoo, J., & Voong, K. R. (2021) · The Oncologist · doi:10.1002/onco.13900 · Cited by 76
Sabbatino, F., Marra, A., Liguori, L., Scognamiglio, G., Fusciello, C., Botti, G., Ferrone, S., & Pepe, S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0439-2 · Cited by 74
Interdisciplinary multimodality management of stage III nonsmall cell lung cancer
Huber, R. M., Ruysscher, D. D., Hoffmann, H., Reu, S., & Tufman, A. (2019) · European Respiratory Review · doi:10.1183/16000617.0024-2019 · Cited by 76
Cho, Y., Kim, Y., Chamseddine, I. M., Lee, W. H., Kim, H. R., Lee, I. J., Hong, M. H., Cho, B. C., Lee, C. G., Cho, S., et al. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.01.007 · Cited by 80
Self-citationHou, Y., Yang, K., Wang, L., Wang, J., Huang, X., Piffkó, A., Luo, S. Z., Yu, X., Rao, E., Martinez, C. N., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3206 · Cited by 76
Zhou, Q. H., Pan, Y., Yang, X., Zhao, Y., Han, G., Pang, Q., Zhang, Z., Wang, Q., Yao, J., Wang, H., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.024 · Cited by 80
Self-citationSenan, S., Okamoto, I., Lee, G., Chen, Y., Niho, S., Mak, G., Yao, W., Shire, N. J., Jiang, H., & Cho, B. C. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.12.006 · Cited by 82
Self-citationImmune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R. A. M., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13081 · Cited by 70
Perrinjaquet, C., Desbaillets, N., & Hottinger, A. F. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000686 · Cited by 78
Beyond PD-L1 Markers for Lung Cancer Immunotherapy
Wojas‐Krawczyk, K., Kalinka‐Warzocha, E., Grenda, A., Krawczyk, P. A., & Milanowski, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081915 · Cited by 79
Management of Lung Cancer During the COVID-19 Pandemic
Singh, A. P., Berman, A. T., Marmarelis, M. E., Haas, A. R., Feigenberg, S. J., Braun, J., Ciunci, C. A., Bauml, J. M., Cohen, R. B., Kucharczuk, J. C., et al. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00286 · Cited by 73
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus
Mineo, M., Lyons, S. M., Zdioruk, M. I., von Spreckelsen, N., Ferrer-Luna, R., Ito, H., Alayo, Q. A., Kharel, P., Giantini-Larsen, A., Fan, W. Y., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.015 · Cited by 73
Suazo-Zepeda, E., Bokern, M. P., Vinke, P. C., Hiltermann, T. J. N., de Bock, G. H., & Sidorenkov, G. A. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02996-3 · Cited by 82
Yang, T., Hao, L., Yang, X., Luo, C., Wang, G., Cai, C. L., Qi, S., & Li, Z. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049123 · Cited by 77
Hingorani, D. V., Allevato, M. M., Camargo, M. F., Lesperance, J., Quraishi, M. A., Aguilera, J. A., Pietryga, I. F., Scanderbeg, D. J., Wang, Z., Molinolo, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31601-z · Cited by 79
Combining immunotherapy and radiotherapy in lung cancer
Bhalla, N., Brooker, R. C., & Brada, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.107 · Cited by 74
Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study
Bullement, A., Latimer, N. R., & Bell‐Gorrod, H. (2018) · Value in Health · doi:10.1016/j.jval.2018.10.007 · Cited by 71
Dudnik, E., Bshara, E., Grubstein, A., Fridel, L., Shochat, T., Roisman, L. C., Ilouze, M., Rozenblum, A. B., Geva, S., Zer, A., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.044 · Cited by 75
Perrone, F., Minari, R., Bersanelli, M., Bordi, P., Tiseo, M., Favari, E., Sabato, R., & Buti, S. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000321 · Cited by 71
Stereotactic ablative radiotherapy for colorectal cancer liver metastasis
Wang, H., Li, X., Peng, R., Wang, Y., & Wang, J. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.018 · Cited by 84
Metadata
- Authors
- Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.-C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro Carpeño, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P. A., & Özgüroğlu, M.
- Affiliations
- Institut Gustave Roussy (FR)
- From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) — all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville — both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and...
- ORCID
- Antonia, Scott J.
- Villegas, Augusto
- Daniel, Davey
- Vicente, David
- Murakami, Shuji
- Hui, Rina
- Yokoi, Takashi
- Chiappori, Alberto
- Lee, Ki H.
- Cho, Byoung C.
- Quantin, Xavier
- Tokito, Takaaki
- Planchard, David
- Kim, Young-Chul
- Karapetis, Christos S.
- Hiret, Sandrine
- Ostoros, Gyula
- Kubota, Kaoru
- Gray, Jhanelle E.
- Paz-Ares, Luis
- Jiang, Haiyi
- Huang, Yifan
- Özgüroğlu, Mustafa
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-16
- Volume
- 377
- Issue
- 20
- Pages
- 1919-1929
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2753065806
- Cited by
- 4,593
- References
- 22
- Citations by year
- 2026: 380 · 2025: 463 · 2024: 496 · 2023: 548 · 2022: 555 · 2021: 625 · 2020: 563 · 2019: 463 · 2018: 451 · 2017: 46
- FWCI
- 183.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- HAL (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Cancer Research UK (20465)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- durvalumab, non-small cell lung cancer, stage III NSCLC, consolidation therapy, chemoradiotherapy, PD-L1 inhibitors, progression-free survival, overall survival, objective response rate, locally advanced unresectable lung cancer, immune checkpoint inhibitors, platinum-based chemotherapy, radiotherapy, distant metastasis, treatment safety, adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, Chemoradiotherapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.